Neoplasms

Blood and Lymph Conditions

All Conditions

Immune System Diseases

Urinary Tract, Sexual Organs, and Pregnancy Conditions

Diseases and Abnormalities at or Before Birth

Digestive System Diseases

Heart and Blood Diseases

Symptoms and General Pathology

Rare Diseases

Leukemia

Precursor Cell Lymphoblastic Leukemia-Lymphoma

Leukemia, Lymphoid

Wilms Tumor

Hepatic Veno-Occlusive Disease

Lymphoma

Neoplasms by Histologic Type

Hematologic Diseases

Lymphoproliferative Disorders

Lymphatic Diseases

Immunoproliferative Disorders

Kidney Neoplasms

Urologic Neoplasms

Urogenital Neoplasms

Syndrome

Neoplastic Syndromes, Hereditary

Urogenital Diseases

Female Urogenital Diseases

Pregnancy Complications

Female Urogenital Diseases and Pregnancy Complications

Kidney Diseases

Urologic Diseases

Male Urogenital Diseases

Genetic Diseases, Inborn

Liver Diseases

Gastrointestinal Diseases

Vascular Diseases

Acute Lymphoblastic Leukemia

Lymphoblastic Lymphoma

Acute Graft Versus Host Disease

Wilms' Tumor

Hepatic Veno-occlusive Disease

Lymphosarcoma

Antineoplastic Agents

All Drugs and Chemicals

Antimitotic Agents

Pateints treated for a nephrobalstoma or ALL in childhood or adolescence

Drawing blood to realize a genetic analysis for susceptibility to hepatic VOD.

Blood test for genetic analysis

Denise Jolivot, MD

Sybille Lazareff, CRA

Anne Lutun, MD

Liana Carausu, MD

Claire Briandet, MD

Hélène Sudour-Bonnange, MD

Arnauld Verschuur, MD

Caroline Thomas, MD

Joy Benabida, MD

Lauriane Lemelle, MD

Virginie Gandemer, MD

Yves Reguerre, MD

Pascale Blouin, MD

Dominique Valteau-Couanet, MD

Isabelle Pellier, MD

Hepatic veno-occlusive diseases (VOD) during cancer treatment in children are serious toxicities that have occurred with interruptions of chemotherapy and risk of relapse. In addition, these toxicities have a negative impact on the patient's quality of life, serious long-term sequelae and are potentially fatal in children.

The risk factors associated with the occurrence of these complications are, to date, unknown, at the exception to the exposition to certain treatments (6-thioguanine, busulfan, actinomycin D, radiotherapy, etc.). To understand the effects of this toxicity and those of susceptibility to the disease becomes a major issue in the treatment of these children.

Case-control study, nested in two French multicenter cohorts, on pharmacognenetic, biological and clinical susceptibility factors associated with the occurrence of hepatic veno-occlusive disease during the anticancer treatment for nephroblastoma or acute lymphoblastic leukemia, with centralized genetic analysis.

After obtaining consent (patient or parents for minor patients), a blood sample is collected during the routine follow-up consultation and tubes are sent directly to Paris for the pharmacogenetic analysis at the end of the study.

Pharmacogenetic Study of Antimitotic Therapies Involved in Hepatic VOD in Children With Nephroblastoma or ALL

Pharmacogenetic Study of Antimitotic Therapies Involved in Hepatic Veno-occlusive Disease in Children With Nephroblastoma or Acute Lymphoblastic Leukemia

Illumina's "Human Omni2.5-8 v1.3" microarrays explore more than 2,600,000 genetic variants, thus covering the entire genome with more than 300,000 genetic biomarkers in exons.

Age, sociodemographics, personal and cancer history.

University Hospital, Angers

Spots Global Cancer Trial Database for blood test for genetic analysis